Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases

BACKGROUND: The development of a clinically useful fibroblast growth factor 21 (FGF21) hormone has been impeded by its inherent instability and weak FGF receptor (FGFR) binding affinity. There is an urgent need for innovative approaches to overcome these limitations. METHODS: We devised a structure-...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:EBioMedicine
Prif Awduron: Zhao, Longwei, Niu, Jianlou, Lin, Huan, Zhao, Jing, Liu, Yang, Song, Zihui, Xiang, Congshang, Wang, Xiaojie, Yang, Yong, Li, Xiaokun, Mohammadi, Moosa, Huang, Zhifeng
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Elsevier 2019
Pynciau:
Research paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6838362/
https://ncbi.nlm.nih.gov/pubmed/31631034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.09.052
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg